Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
In patients with Duchenne Muscular Dystrophy who have an exon 51 mutation, do you treat with both prednisone and Eteplirsen?
What are common side effects to look out for with Eteplirsen?
Related Questions
Beyond fatigability, what distinctive features of diplopia characterize myasthenia gravis?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
How frequently do you re-evaluate AChR and MuSK antibodies in patients with clinical and electrodiagnostic evidence of seronegative myasthenia gravis?
How could you utilize neuromuscular ultrasound as a marker of disease progression/treatment response in CIDP?
How do you counsel patients with mild congenital myopathy about exercise limitations?
How do you use serum IgG levels when treating with FcRN inhibitors?
How do you use total IgG levels, if at all, to guide plasma exchange for myasthenia gravis exacerbations?
What treatments, after appropriate dose reductions/delays, do you offer for patients with oxaliplatin-induced cold allodynia/dysesthesia?
How do you approach sequentially tapering combination therapy (i.e., IVIG, mycophenolate, rituximab) for dermatomyositis that is in remission?
How do you counsel patients with dermatomyositis on sun protection?